A globally-renowned prostate cancer surgeon shares the latest advancements in the field and stresses the importance of early ...

Some avid watchers of football broadcasts have no doubt become aware of a drug called Pluvicto. That’s because commercials ...

Despite several recent advancements in the field of prostate cancer (PC) treatment, there remain distinct gaps in the current ...

Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like wandering through a foggy wilderness, quiet and cautious, afraid that any ...

Dr Daniel Petrylak discusses groundbreaking advancements in prostate cancer treatment, including genetic mutations, PARP ...

Prostate cancer has become a significant health concern among men, being the second leading cause of death in the United States. While the survival rate in men remains high, those who have advanced, ...

Scripps Health in recent years has been using what are described as “medical smart bombs” to help treat patients who have advanced prostate cancer. And with the introduction of new technology in ...

MONTREAL, July 3, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, as of July 2, 2025, Pluvicto ® (lutetium (177 Lu) vipivotide tetraxetan injection) is ...

LOS ANGELES, July 09, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, ...

ATNM-400 demonstrated significant in vitro tumor cell killing when used in combination with AR-targeting agents, such as enzalutamide (Xtandi ®) The ATNM-400 enzalutamide combination produced superior ...